Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase 2 Study of Veliparib ABT-888 and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma HGG without H3 K27M or BRAFV600 Mutations
Study Type: Treatment
Phase: II
NCTID: NCT03581292
Principal Investigator:
Kevin Ginn
A Phase II Randomized Trial of Proton Vs. Photon Therapy IMRT For Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas
A Phase II Trial of Chemotherapy followed by Response-Based Whole Ventricular Spinal Canal Irradiation WVSCI for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Study Type: Treatment
Phase: II
NCTID: NCT04684368
Principal Investigator:
Keith August
Advancing Treatment for Pediatric Craniopharyngioma: Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy
Study Type: Other
Phase: Feasibility/Pilot
NCTID: NCT03610906
Principal Investigator:
Kevin Ginn
A Phase III Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features
Study Type: Treatment
Phase: III
NCTID: NCT05382338
Principal Investigator:
Keith August
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine DFMO
Study Type: Prevention
Phase: II
NCTID: NCT02679144
Principal Investigator:
Kevin Ginn
Phase III Trial Of Post-Surgical Single Fraction Stereotactic Radiosurgery SRS Compared With Fractionated SSs FSRS For Resected Metastatic Brain Disease
A Phase 2 Study of Dabrafenib NSC 763760 with Trametinib NSC 763093 after Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma HGG
Study Type: Treatment
Phase: II
NCTID: NCT03919071
Principal Investigator:
Keith August
A Randomized Phase II Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where cisplatin-Based Treatment is Not an Option
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
Study Type: Treatment
Phase: II
NCTID: NCT04696029
Principal Investigator:
Kevin Ginn